La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

X4 Pharmaceuticals Crescita futura

Future criteri di controllo 3/6

Si prevede che gli utili di X4 Pharmaceuticals diminuiranno a 8% all'anno, mentre si prevede che i suoi ricavi annuali cresceranno a 54.8% all'anno. Si prevede che l'EPS crescerà di 4.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà 46.3% in 3 anni.

Informazioni chiave

-8.0%

Tasso di crescita degli utili

4.8%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	35.4%
Tasso di crescita dei ricavi	54.8%
Rendimento futuro del capitale proprio	46.3%
Copertura analitica	Good
Ultimo aggiornamento	13 Aug 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:48Q - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	101	-77	-105	N/A	6
12/31/2025	44	-111	-92	N/A	7
12/31/2024	6	-43	N/A	N/A	7
6/30/2024	1	18	-120	-112	N/A
3/31/2024	N/A	-129	-104	-104	N/A
12/31/2023	N/A	-101	-97	-97	N/A
9/30/2023	N/A	-111	-88	-88	N/A
6/30/2023	N/A	-131	-86	-86	N/A
3/31/2023	N/A	-96	-83	-83	N/A
12/31/2022	N/A	-96	-77	-77	N/A
9/30/2022	N/A	-103	-77	-77	N/A
6/30/2022	N/A	-102	-72	-72	N/A
3/31/2022	N/A	-100	-73	-73	N/A
12/31/2021	N/A	-103	-72	-71	N/A
9/30/2021	N/A	-85	-70	-69	N/A
6/30/2021	N/A	-82	-71	-69	N/A
3/31/2021	N/A	-78	-63	-62	N/A
12/31/2020	3	-62	-60	-59	N/A
9/30/2020	3	-55	-52	-51	N/A
6/30/2020	3	-55	-50	-49	N/A
3/31/2020	3	-53	-53	-52	N/A
12/31/2019	N/A	-53	-48	-48	N/A
9/30/2019	N/A	-55	-46	-46	N/A
6/30/2019	N/A	-46	-40	-39	N/A
3/31/2019	N/A	-40	-31	-31	N/A
12/31/2018	N/A	-36	-25	-25	N/A
9/30/2018	N/A	-31	-23	-23	N/A
12/31/2017	N/A	-25	N/A	-21	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che gli utili di 48Q diminuiranno nei prossimi 3 anni ( -8% all'anno).

Guadagni vs Mercato: Si prevede che gli utili di 48Q diminuiranno nei prossimi 3 anni ( -8% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 48Q diminuiranno nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 48Q ( 54.8% all'anno) crescerà più rapidamente del mercato German ( 5.2% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 48Q ( 54.8% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 48Q sarà molto alto tra 3 anni ( 46.3 %).

X4 Pharmaceuticals Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

X4 Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

X4 Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Small Cap Comp Value Index

X4 Pharmaceuticals, Inc. Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (Cn) and Initiation of Pivotal Phase 3 Cn Trial

New major risk - Financial position

X4 Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome

X4 Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 21, 2024

X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

X4 Pharmaceuticals, Inc. Receives A Deficiency Letter from Nasdaq Regarding Bid Price Rule

X4 Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

X4 Pharmaceuticals Announces Submission of New Drug Application (Nda) to U.S. Fda for Mavorixafor in Whim Syndrome

Now 23% undervalued after recent price drop

Director recently sold €125k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. announced that it expects to receive $115 million in funding

X4 Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

X4 Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

X4 Pharmaceuticals Announces Positive Top-Line Results from 4Whim Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in Whim Syndrome

X4 Pharmaceuticals, Inc. Announces Executive Changes

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

X4 Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022

X4 Pharmaceuticals, Inc. Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

X4 Pharmaceuticals, Inc. announced that it expects to receive $55.763275 million in funding from New Enterprise Associates, Inc., Acorn Bioventures, Lumira Ventures, Bain Capital Life Sciences Investors, LLC, OrbiMed Advisors LLC, Hercules Capital, Inc.

X4 Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

X4 Pharmaceuticals, Inc. Presents New Clinical and Scientific Data At 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

X4 Pharmaceuticals, Inc. Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Microcap Value Index

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021

X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract

X4 Pharmaceuticals, Inc. Provides an Update on its Lead Product Candidate, Mavorixafor, a Novel Small Molecule Currently Being Evaluated in a Phase 3 Clinical Trial

New 90-day high: €8.30

Revenue beats expectations

X4 Pharmaceuticals, Inc. Provides an Update on Its Lead Product Candidate, Mavorixafor

X4 Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 04, 2021

New 90-day high: €7.30

New 90-day high: €6.15

X4 Pharmaceuticals, Inc. Appoints Diego Cadavid, M.D., as Chief Medical Officer

X4 Pharmaceuticals, Inc. Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of Whim Syndrome

X4 Pharmaceuticals, Inc. Announces the Appointment of Art Taveras as Chief Scientific Officer

New 90-day low: €5.00

X4 Pharmaceuticals, Inc. has Re-Assessed the Impacts of the Continuing COVID-19 Pandemic on the Ongoing Phase 1B Dose-Escalation Trial

X4 Pharmaceuticals, Inc. Announces Board Changes, Effective October 5, 2020

New 90-day low - €5.95

New 90-day low - €6.25

X4 Pharmaceuticals, Inc. to Report Q2, 2020 Results on Jul 30, 2020

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell 3000 Growth Index

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita